Research Webinars, • 8/7/24 Mutation-Specific Epigenetic Reprogramming of Hematopoietic Stem Cells in AML Previous Latest Research Findings From the Ongoing NIH RUNX1 Natural History Study Next An Approach to Screening Drugs for Preventing Disease Progression in Patients with RUNX1-FPD You Might Also Like Limiting Cancer Risk Through Physical Activity Introduction to the Sirolimus Pilot Study (8.9.24) On a Journey Toward a Cure - May 1st RRP Community Workshop Module 2: The Therapeutic Potential of Increasing RUNX1 Activity Using a Drug Crosstalk Between Transcription Factors, Methyltransferases and Tyrosine Kinases
Research Webinars, • 8/7/24 Mutation-Specific Epigenetic Reprogramming of Hematopoietic Stem Cells in AML Previous Latest Research Findings From the Ongoing NIH RUNX1 Natural History Study Next An Approach to Screening Drugs for Preventing Disease Progression in Patients with RUNX1-FPD You Might Also Like Limiting Cancer Risk Through Physical Activity Introduction to the Sirolimus Pilot Study (8.9.24) On a Journey Toward a Cure - May 1st RRP Community Workshop Module 2: The Therapeutic Potential of Increasing RUNX1 Activity Using a Drug Crosstalk Between Transcription Factors, Methyltransferases and Tyrosine Kinases
